Stay updated on ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.

Latest updates to the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page
- Check5 days agoChange DetectedResults posting information was added (Results First Posted 2026-02-17; Results First Submitted 2024-03-25), and the study now includes Exploratory Arm 1 and 2 as well as Arm B (RP2D) with related dosing details.SummaryDifference6%

- Check12 days agoChange DetectedThe revision label on the page updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page shows a minor site revision from v3.4.0 to v3.4.1; no changes to study content or navigation are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page shows a new revision tag 'Revision: v3.3.4' replacing the previous 'Revision: v3.3.3', a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedLocations information was updated: a new Locations section lists Florida, Minnesota, Ohio, and South Carolina, with the previous state entries removed; the HHS Vulnerability Disclosure link was also removed.SummaryDifference0.5%

- Check91 days agoChange DetectedPubMed publications description was updated to indicate automatic filling from PubMed, and a revision note shows version v3.3.2.SummaryDifference0.1%

Stay in the know with updates to ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.